A dramatic decrease in fee-paying drug and biologic applications in fiscal year 2022 helped push prescription drug user fees up nearly 25% for FY 2024.
PDUFA Fees Push Higher In FY 2024, While Biosimilar Fees Race Downward
Fiscal year 2024 prescription drug user fees skyrocket in part because of a low application volume in FY 2022, while biosimilar user fees continue to drop due to the program’s healthy operating reserve.
